1.
|
Phase: Phase III
Type: Treatment
Status: Active
Age: 75 and under
Sponsor: Other
Protocol IDs: CNR-9506, EU-95024, NCT00002702
|
|
2.
|
Phase: Phase III
Type: Supportive care, Treatment
Status: Active
Age: 20 to 80
Sponsor: Other
Protocol IDs: TCVGH-957001A, 941117/C05186, NCT00308880
|
|
3.
|
Phase: Phase III
Type: Supportive care, Treatment
Status: Active
Age: 18 and over
Sponsor: Other
Protocol IDs: 186-03, ETH136-03D, NCT00206752
|
|
4.
|
Phase: Phase III
Type: Treatment
Status: Active
Age: 18 to 70
Sponsor: Pharmaceutical / Industry
Protocol IDs: EGF102988, NCT00424255
|
|
5.
|
Phase: Phase III
Type: Treatment
Status: Active
Age: 18 and over
Sponsor: Other
Protocol IDs: DAHANCA 19, Ethical Comittee: 20070091, DKMA: 2612-3486, NCT00496652
|
|
6.
|
Phase: Phase III
Type: Supportive care, Treatment
Status: Active
Age: Not specified
Sponsor: Other
Protocol IDs: H07-02297, H07-02297, NCT00615420
|
|
7.
|
Phase: Phase III
Type: Diagnostic, Treatment
Status: Active
Age: 18 and over
Sponsor: Other
Protocol IDs: WMS-PET-NECK, WMS-PET-NECK, ISRCTN13735240, EU-20856, MREC-07/Q1604/35, UKCRN ID: 3799, NCT00720070
|
|
8.
|
Phase: Phase III
Type: Biomarker/Laboratory analysis, Treatment
Status: Approved-not yet active
Age: 19 and over
Sponsor: Other
Protocol IDs: H09-03090, NCT01039298
|
|
9.
|
Phase: Phase II, Phase I
Type: Treatment
Status: Active
Age: 18 and over
Sponsor: Other
Protocol IDs: NA-15-0006, NCT00137475
|
|
10.
|
Phase: Phase II, Phase I
Type: Biomarker/Laboratory analysis, Treatment
Status: Active
Age: 18 and over
Sponsor: Other
Protocol IDs: CHUV-CEPO-161-05, EU-20627, NCT00357617
|
|
11.
|
Phase: Phase II, Phase I
Type: Treatment
Status: Active
Age: 18 and over
Sponsor: Other
Protocol IDs: 2005781-01H, OTT 05-06, NCT00426504
|
|
12.
|
Phase: Phase II, Phase I
Type: Treatment
Status: Active
Age: Over 18
Sponsor: Pharmaceutical / Industry
Protocol IDs: UCIRB #14735B, GV-001.010 (TNF-ELF), NCT00496236
|
|
13.
|
Phase: Phase II, Phase I
Type: Biomarker/Laboratory analysis, Treatment
Status: Active
Age: Over 18
Sponsor: Other
Protocol IDs: CHIRON 2008-01, NCT00714649
|
|
14.
|
Phase: Phase II, Phase I
Type: Treatment
Status: Active
Age: 18 to 90
Sponsor: Other
Protocol IDs: J08101, CA180123, NCT00882583
|
|
15.
|
Phase: Phase II, Phase I
Type: Biomarker/Laboratory analysis, Treatment
Status: Active
Age: 18 and over
Sponsor: Pharmaceutical / Industry
Protocol IDs: P276-00/31/08, P276-00/31/08, NCT00899054
|
|
16.
|
Phase: Phase II, Phase I
Type: Supportive care, Treatment
Status: Active
Age: 18 and over
Sponsor: Pharmaceutical / Industry
Protocol IDs: 603EUSA03, NCT00901732
|
|
17.
|
Phase: Phase II, Phase I
Type: Treatment
Status: Active
Age: 18 to 85
Sponsor: Other
Protocol IDs: CLIN-003-09S, NCT00953849
|
|
18.
|
Phase: Phase II
Type: Natural history/Epidemiology, Treatment
Status: Active
Age: 18 to 70
Sponsor: Other
Protocol IDs: HNO-FMISO-FU, NCT00180180
|
|
19.
|
Phase: Phase II
Type: Treatment
Status: Active
Age: 18 and over
Sponsor: Other
Protocol IDs: UHN REB 02-0832-C, NCT00252473
|
|
20.
|
Phase: Phase II
Type: Treatment
Status: Active
Age: 18 and over
Sponsor: Other
Protocol IDs: 06U.195, NCT00358007
|
|
21.
|
Phase: Phase II
Type: Treatment
Status: Active
Age: Over 18
Sponsor: Other
Protocol IDs: 2004-01avr-074, NCT00389727
|
|
22.
|
Phase: Phase II
Type: Treatment
Status: Active
Age: 18 and over
Sponsor: Other
Protocol IDs: 2006-0940, NCT00494182
|
|
23.
|
Phase: Phase II
Type: Treatment
Status: Active
Age: 19 and over
Sponsor: Other
Protocol IDs: F070824015, UAB 0718, NCT00570232
|
|
24.
|
Phase: Phase II
Type: Treatment
Status: Active
Age: Over 18
Sponsor: Other
Protocol IDs: 07-0142, NCT00593840
|
|
25.
|
Phase: Phase II
Type: Treatment
Status: Active
Age: 18 and over
Sponsor: Other, Pharmaceutical / Industry
Protocol IDs: CALACASS-AACER, AACER, MERCK-CALACASS-AACER, INCA-RECF0623, EUDRACT-2007-004384-22, NCT00875849
|
